Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial

Abstract

Background:

Vorapaxar inhibits the thrombin-mediated activation of platelets, reduces thrombotic events in patients with myocardial infarction or peripheral arterial disease while increasing bleeding. In the TRA 2°P-TIMI 50 trial, we observed a nominally significant interaction between low body weight and the reduced efficacy of vorapaxar.

Methods:

We investigated the relationship between body weight and the efficacy and safety of vorapaxar within a multinational, randomized, double-blind, placebo-controlled trial of vorapaxar in patients with atherosclerosis. This analysis was performed among 20,138 patients with a clinical indication for vorapaxar.

Results:

Compared with patients weighing 60 kg or more, patients weighing less than 60 kg were older, more frequently women, Asian and had renal insufficiency (each P<0.001). The efficacy of vorapaxar with respect to cardiovascular death, myocardial infarction and stroke showed a significant interaction with patients’ weight (P_interaction<0.03). However among patients younger than 65 years, vorapaxar reduced the primary endpoint regardless of weight (weight ≥60 kg: 6.4% vs. 8.1%, hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.65–0.86; weight <60 kg: 5.4% vs. 7.2%, HR 0.75, 95% CI 0.37–1.49, P_interaction=0.98). Among patients aged 65 years and older, the efficacy of vorapaxar diminished in patients weighing less than 60 kg (high weight: 10.4% vs. 12.6%, HR 0.81, 95% CI 0.69–0.95; low weight: 16.1% vs. 9.0%, HR 1.62, 95% CI 0.95–2.76, P_interaction=0.01). The relative increase in bleeding with vorapaxar was not modified by weight (all P_interaction>0.05).

Conclusions:

Vorapaxar reduced vascular events and improved net clinical outcome regardless of body weight in younger patients. Elderly patients with low weight may not be good candidates for aggressive secondary prevention with vorapaxar added to standard therapy.

Clinical Trial Registration:

URL: http://www.clinicaltrials.gov Unique identifier: NCT00526474

Keywords

Atherosclerosis platelet inhibitor vorapaxar body weight

Get full access to this article

View all access options for this article.

References

Das

Alexander

Chen

, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-segment elevation myocardial infarction: results from the NCDR (National Cardiovascular Data Registry). JACC 2011; 58: 2642–2650.

Romero-Corral

Montori

Somers

, et al. Association of body weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368: 666–678.

Jackson

Stampfer

MJ.

Maintaining a healthy body weight is paramount. JAMA Intern Med 2014; 174: 23–24.

Wagner

Angiolillo

Ten Berg

, et al. Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. J Thromb Thrombolysis 2014; 38: 127–136.

Wrishko

RE1

Ernest

II Small

, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 2009; 49: 984–998.

Erlinge

Ten Berg

Foley

, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol 2012; 60: 2032–2040.

Morrow

Braunwald

Bonaca

, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404–1413.

Magnani

Bonaca

Braunwald

, et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc 2015; 4: e001505.

Morrow

Scirica

Fox

, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009; 158: 335–341.e3.

10.

Rocca

Fox

KAA

Ajjan

, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J 2018; 39: 1672–1686f.

11.

Breet

NJ1

van Donkersgoed

van Werkum

, et al. Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? Neth Heart J 2011; 19: 279–284.

12.

Olivier

Schnabel

Weber

, et al. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel. J Thromb Thrombolysis 2016; 42: 84–89.

13.

Patrono

Rocca

Type 2 diabetes, obesity, and aspirin responsiveness. J Am Coll Cardiol 2017; 69: 613–615.

14.

Zaccardi

Pitocco

Willeit

, et al. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials. Atherosclerosis 2015; 240: 439–445.

15.

Alexander

KP1

Newby

Cannon

, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2549–2569.

16.

Alexander

KP1

Newby

Armstrong

, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2570–2589.

17.

Roe

Goodman

Ohman

, et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013; 128: 823–833.

18.

Andreotti

Rocca

Husted

, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36: 3238–3249.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.60 MB